Thierry Nordmann
banner
tnordmann.bsky.social
Thierry Nordmann
@tnordmann.bsky.social
Skin-Scientist, MD-PhD, Applying Spatial & Single-Cell Clinical Proteomics in Dermatology, Husband, Father of 3 💫🔬
A must-read, landmark paper by @lisaschweizer.bsky.social
- hands down one of the most accomplished scientists I know. Congratulations👏 @mannlab.bsky.social @lengyel-ovca-lab.bsky.social
bsky.app/profile/mann...
June 26, 2025 at 6:39 PM
Reposted by Thierry Nordmann
Our paper on ovarian cancer #LGSC is out in @Cancer_Cell. Using deep visual proteomics #DVP and spatial transcriptomics, we mapped how non-invasive tumors become deadly ovarian disease, and found a promising new treatment combination.
www.cell.com/cancer-cell/...
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression
Schweizer et al. profile the tumor progression from non-invasive serous borderline tumors of the ovary to metastatic low-grade serous ovarian cancer. By integrating cell-type resolved Deep Visual Prot...
www.cell.com
June 26, 2025 at 3:20 PM
Reposted by Thierry Nordmann
Since April, @tnordmann.bsky.social has been leading a research Group @mpibiochem.bsky.social. He has now been awarded the prestigious Oscar Gans Prize by the German Dermatological Society. Congratulations and welcome!

#award #dermatology #proteomics @mannlab.bsky.social
May 2, 2025 at 11:25 AM
Reposted by Thierry Nordmann
In patients with diffuse intrinsic pontine glioma, a rare, fast-growing and fatal pediatric brain tumor, local delivery of B7-H3 targeting CAR T cells was feasible and well tolerated with a median overall survival of 19.8 months, according to a trial reported in Nature Medicine. #MedSky 🧪
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial - Nature Medicine
In the final report of a phase 1 trial evaluating intracerebroventricular B7-H3-targeting CAR T cells in children and young adults with diffuse intrinsic pontine glioma, repeated intracranial infusions were feasible and well tolerated with a median overall survival of 19.8 months and 3 patients surviving over 40 months from diagnosis.
go.nature.com
January 17, 2025 at 1:21 PM
Reposted by Thierry Nordmann
Our mipDVP workflow integrates 22-marker imaging with Deep Visual Proteomics to spatially map cell-type proteomes in hot/cold tumors, revealing distinct immune landscapes, macrophage barriers, T cell adaptations to hypoxia & tumor heterogeneity. Online in Molecular Cell.
doi.org/10.1016/j.mo...
January 14, 2025 at 4:24 PM
Reposted by Thierry Nordmann
My favorite books, 2024
December 28, 2024 at 6:31 PM
Reposted by Thierry Nordmann
Looking forward to a fabulous 2025, full of happiness and scientific achievements! 🔬💫
December 20, 2024 at 2:21 PM
Reposted by Thierry Nordmann
Spatial proteomics is Method of the Year 2024 @naturemethods.bsky.social!🎉🤩 Grateful to share our perspective on spatial proteomics with the great Matthias Mann and Andreas Mund, alongside inspiring colleagues shaping this exciting field - this is just the beginning 💫
www.nature.com/articles/s41...
A new understanding of tissue biology from MS-based proteomics at single-cell resolution - Nature Methods
Spatial mass spectrometry (MS)-proteomics is a rapidly evolving technology, particularly in the form of Deep Visual Proteomics (DVP), which allows the study of single cells directly in their native en...
www.nature.com
December 7, 2024 at 8:43 PM
Reposted by Thierry Nordmann
Spatial proteomics is Method of the Year 2024 @naturemethods.bsky.social!🎉🤩 Grateful to share our perspective on spatial proteomics with the great Matthias Mann and Andreas Mund, alongside inspiring colleagues shaping this exciting field - this is just the beginning 💫
www.nature.com/articles/s41...
A new understanding of tissue biology from MS-based proteomics at single-cell resolution - Nature Methods
Spatial mass spectrometry (MS)-proteomics is a rapidly evolving technology, particularly in the form of Deep Visual Proteomics (DVP), which allows the study of single cells directly in their native en...
www.nature.com
December 7, 2024 at 8:43 PM
Reposted by Thierry Nordmann
After long-time review, #nanoSPLITS is finally published. I am deeply grateful to my colleagues who made this work possible, especially @cajunscience.bsky.social. I am also grateful to the support of our single-cell proteomics community during the peer review on Nature Communication!
December 6, 2024 at 12:41 AM
Reposted by Thierry Nordmann
A bench-to-bedside targeted therapy story!

Fatal disease ➡️ patient samples ➡️ deep proteomics ➡️ find target (jak/stat) ➡️ realize drugs exist ➡️ try drugs in lab ➡️ it works! ➡️ give drugs to patients ➡️ holy cow it actually works!!!! ➡️ save lives.

This is the dream. Nice work @tnordmann.bsky.social
Wow—one of the most impressive bench-to-bedside stories you’re ever going to see out today @Nature

Spatial proteomics of potentially fatal toxic epidermal necrolysis/Stevens-Johnson Syndrome drug reactions identifies JAK/STAT pathway inhibition as effective therapy!

www.nature.com/articles/s41...
November 27, 2024 at 2:53 PM
Reposted by Thierry Nordmann
Wow—one of the most impressive bench-to-bedside stories you’re ever going to see out today @Nature

Spatial proteomics of potentially fatal toxic epidermal necrolysis/Stevens-Johnson Syndrome drug reactions identifies JAK/STAT pathway inhibition as effective therapy!

www.nature.com/articles/s41...
November 24, 2024 at 2:18 AM
Reposted by Thierry Nordmann
Science twitter is dead! Long live science twitter! 🦋
November 18, 2024 at 1:05 PM
Reposted by Thierry Nordmann
First BlueSky post :)
November 16, 2024 at 5:26 PM
Reposted by Thierry Nordmann
The Dawn of Spatial Medicine
Until now, spatial omics was used to understand human biology. That changed when it saved lives of patients with a fatal skin condition.
In the new Ground Truths
erictopol.substack.com/p/the-dawn-o...
The Dawn of Spatial Medicine
For the first time spatial omics leads to a lifesaving treatment
erictopol.substack.com
October 26, 2024 at 2:40 PM